Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 4 Researches
7
USERS' SCORE
Moderately Good
Based on 16 Reviews
7.7
Supplement Facts
Serving Size: 2 Veg Capsules
Amount Per Serving
%DV
Alpha GPC (L-alpha-glycerylphosphorylcholine)
600 mg
*
Top Medical Research Studies
9
We investigated how alpha-glycerophosphocholine (alpha-GPC) can aid in recovery for individuals who have recently suffered strokes or transient ischemic attacks. In this multicenter clinical trial involving 2044 patients, alpha-GPC was given after the event—first through injections for 28 days and then as a daily oral supplement for five months.
Throughout the treatment, we measured cognitive recovery using various scales, including the Mathew Scale, Mini Mental State Test, Crichton Rating Scale, and Global Deterioration Scale. Over the course of just 28 days, patients showed significant improvements in their mental recovery, with the Mathew Scale score increasing by an impressive 15.9 points. By the end of the five-month study, we noticed that many participants achieved near-normal cognitive scores, with 71% experiencing no cognitive decline.
While some patients did report mild adverse effects like heartburn and nausea, the overall tolerability was excellent, with only 2.14% needing to discontinue treatment due to side effects. We learned that alpha-GPC has a promising role in supporting cognitive recovery following strokes and transient ischemic attacks, highlighting its potential benefits in rehabilitation settings.
Throughout the treatment, we measured cognitive recovery using various scales, including the Mathew Scale, Mini Mental State Test, Crichton Rating Scale, and Global Deterioration Scale. Over the course of just 28 days, patients showed significant improvements in their mental recovery, with the Mathew Scale score increasing by an impressive 15.9 points. By the end of the five-month study, we noticed that many participants achieved near-normal cognitive scores, with 71% experiencing no cognitive decline.
While some patients did report mild adverse effects like heartburn and nausea, the overall tolerability was excellent, with only 2.14% needing to discontinue treatment due to side effects. We learned that alpha-GPC has a promising role in supporting cognitive recovery following strokes and transient ischemic attacks, highlighting its potential benefits in rehabilitation settings.
Read More
8
We explored the effects of alpha-GPC on the brain's response to stroke by comparing its impact alongside other neuroprotective treatments. In conducting experimental studies on 18 rats, we induced temporary strokes by restricting blood flow in the brain.
Using light and electron microscopy, we examined the brain structures like the cerebral cortex and cerebellum to assess cell damage and recovery processes. We observed that alpha-GPC, as well as another agent called cerebrolysin, notably improved the resilience of neurons against ischemic damage. They seemed to slow down the process of cell death and foster adaptive changes, such as enhancing cellular structures responsible for protein synthesis and storage.
In contrast, treatments like piracetam and vinpocetine didn’t show the same protective benefits. The evidence indicated inadequate energy for cell repair in response to ischemia, leading to concerning signs of neuron stress and cellular damage, including issues in myelin and synapse structure.
Overall, our findings suggest that alpha-GPC plays a positive role in supporting cellular health during stroke conditions, offering hope for neuroprotective therapies in stroke care.
Using light and electron microscopy, we examined the brain structures like the cerebral cortex and cerebellum to assess cell damage and recovery processes. We observed that alpha-GPC, as well as another agent called cerebrolysin, notably improved the resilience of neurons against ischemic damage. They seemed to slow down the process of cell death and foster adaptive changes, such as enhancing cellular structures responsible for protein synthesis and storage.
In contrast, treatments like piracetam and vinpocetine didn’t show the same protective benefits. The evidence indicated inadequate energy for cell repair in response to ischemia, leading to concerning signs of neuron stress and cellular damage, including issues in myelin and synapse structure.
Overall, our findings suggest that alpha-GPC plays a positive role in supporting cellular health during stroke conditions, offering hope for neuroprotective therapies in stroke care.
Read More
8
We set out to understand how alpha-GPC, a neuroprotective drug, can affect stroke recovery by observing its impact on brain structure during ischemic stroke. The study involved 18 rats, where we induced temporary cerebral circulation blockage to mimic stroke conditions. We then treated these rats with alpha-GPC, along with other neurotrophic and nootropic drugs, including cerebrolysin and piracetam.
Our findings revealed that treatment with alpha-GPC led to improved resilience in neurons exposed to ischemic damage. We discovered signs of cellular adaptation and repair, such as changes in the ribosome count and structural integrity of organelles. Importantly, alpha-GPC seemed to prolong the survival of neurons and delay cell death, which suggests a positive role in stroke recovery.
In comparison, rats treated with piracetam and vinpocetin showed concerning signs of energy deficits and functional stress in their neurons, indicating those treatments may not be as effective during the acute phase of stroke. Overall, the study highlights alpha-GPC's potential benefits in supporting neuron health post-stroke, and it raises intriguing questions about how different treatments can work in a complementary or competitive manner.
Our findings revealed that treatment with alpha-GPC led to improved resilience in neurons exposed to ischemic damage. We discovered signs of cellular adaptation and repair, such as changes in the ribosome count and structural integrity of organelles. Importantly, alpha-GPC seemed to prolong the survival of neurons and delay cell death, which suggests a positive role in stroke recovery.
In comparison, rats treated with piracetam and vinpocetin showed concerning signs of energy deficits and functional stress in their neurons, indicating those treatments may not be as effective during the acute phase of stroke. Overall, the study highlights alpha-GPC's potential benefits in supporting neuron health post-stroke, and it raises intriguing questions about how different treatments can work in a complementary or competitive manner.
Read More
Most Useful Reviews
9
Restores recovery
21 people found this helpful
An excellent remedy for my seriously ill child, helping to restore memory, speech, and mood. We have seen consistent improvement over 1.5 years. It's particularly beneficial for those recovering from stroke or TBI, with no side effects like headaches.
Read More
9
Enhances cognitive function
12 people found this helpful
Alpha-GPC is essential for brain health, providing choline for cell membranes and increasing acetylcholine levels. After my mother's stroke, it significantly aided her recovery. Initially, she took 1200 mg daily for six months and now alternates it with other nootropics.
Read More
9
Improved condition
2 people found this helpful
I combined this with citicoline for my mother’s stroke recovery. It's excellent — her foggy memory is clearing, and she’s more active. I experienced significant effects too, feeling more energetic and calm without drowsiness.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 4 Researches
7
- All Researches
9
We investigated how alpha-glycerophosphocholine (alpha-GPC) can aid in recovery for individuals who have recently suffered strokes or transient ischemic attacks. In this multicenter clinical trial involving 2044 patients, alpha-GPC was given after the event—first through injections for 28 days and then as a daily oral supplement for five months.
Throughout the treatment, we measured cognitive recovery using various scales, including the Mathew Scale, Mini Mental State Test, Crichton Rating Scale, and Global Deterioration Scale. Over the course of just 28 days, patients showed significant improvements in their mental recovery, with the Mathew Scale score increasing by an impressive 15.9 points. By the end of the five-month study, we noticed that many participants achieved near-normal cognitive scores, with 71% experiencing no cognitive decline.
While some patients did report mild adverse effects like heartburn and nausea, the overall tolerability was excellent, with only 2.14% needing to discontinue treatment due to side effects. We learned that alpha-GPC has a promising role in supporting cognitive recovery following strokes and transient ischemic attacks, highlighting its potential benefits in rehabilitation settings.
Throughout the treatment, we measured cognitive recovery using various scales, including the Mathew Scale, Mini Mental State Test, Crichton Rating Scale, and Global Deterioration Scale. Over the course of just 28 days, patients showed significant improvements in their mental recovery, with the Mathew Scale score increasing by an impressive 15.9 points. By the end of the five-month study, we noticed that many participants achieved near-normal cognitive scores, with 71% experiencing no cognitive decline.
While some patients did report mild adverse effects like heartburn and nausea, the overall tolerability was excellent, with only 2.14% needing to discontinue treatment due to side effects. We learned that alpha-GPC has a promising role in supporting cognitive recovery following strokes and transient ischemic attacks, highlighting its potential benefits in rehabilitation settings.
Read More
8
We explored the effects of alpha-GPC on the brain's response to stroke by comparing its impact alongside other neuroprotective treatments. In conducting experimental studies on 18 rats, we induced temporary strokes by restricting blood flow in the brain.
Using light and electron microscopy, we examined the brain structures like the cerebral cortex and cerebellum to assess cell damage and recovery processes. We observed that alpha-GPC, as well as another agent called cerebrolysin, notably improved the resilience of neurons against ischemic damage. They seemed to slow down the process of cell death and foster adaptive changes, such as enhancing cellular structures responsible for protein synthesis and storage.
In contrast, treatments like piracetam and vinpocetine didn’t show the same protective benefits. The evidence indicated inadequate energy for cell repair in response to ischemia, leading to concerning signs of neuron stress and cellular damage, including issues in myelin and synapse structure.
Overall, our findings suggest that alpha-GPC plays a positive role in supporting cellular health during stroke conditions, offering hope for neuroprotective therapies in stroke care.
Using light and electron microscopy, we examined the brain structures like the cerebral cortex and cerebellum to assess cell damage and recovery processes. We observed that alpha-GPC, as well as another agent called cerebrolysin, notably improved the resilience of neurons against ischemic damage. They seemed to slow down the process of cell death and foster adaptive changes, such as enhancing cellular structures responsible for protein synthesis and storage.
In contrast, treatments like piracetam and vinpocetine didn’t show the same protective benefits. The evidence indicated inadequate energy for cell repair in response to ischemia, leading to concerning signs of neuron stress and cellular damage, including issues in myelin and synapse structure.
Overall, our findings suggest that alpha-GPC plays a positive role in supporting cellular health during stroke conditions, offering hope for neuroprotective therapies in stroke care.
Read More
8
We set out to understand how alpha-GPC, a neuroprotective drug, can affect stroke recovery by observing its impact on brain structure during ischemic stroke. The study involved 18 rats, where we induced temporary cerebral circulation blockage to mimic stroke conditions. We then treated these rats with alpha-GPC, along with other neurotrophic and nootropic drugs, including cerebrolysin and piracetam.
Our findings revealed that treatment with alpha-GPC led to improved resilience in neurons exposed to ischemic damage. We discovered signs of cellular adaptation and repair, such as changes in the ribosome count and structural integrity of organelles. Importantly, alpha-GPC seemed to prolong the survival of neurons and delay cell death, which suggests a positive role in stroke recovery.
In comparison, rats treated with piracetam and vinpocetin showed concerning signs of energy deficits and functional stress in their neurons, indicating those treatments may not be as effective during the acute phase of stroke. Overall, the study highlights alpha-GPC's potential benefits in supporting neuron health post-stroke, and it raises intriguing questions about how different treatments can work in a complementary or competitive manner.
Our findings revealed that treatment with alpha-GPC led to improved resilience in neurons exposed to ischemic damage. We discovered signs of cellular adaptation and repair, such as changes in the ribosome count and structural integrity of organelles. Importantly, alpha-GPC seemed to prolong the survival of neurons and delay cell death, which suggests a positive role in stroke recovery.
In comparison, rats treated with piracetam and vinpocetin showed concerning signs of energy deficits and functional stress in their neurons, indicating those treatments may not be as effective during the acute phase of stroke. Overall, the study highlights alpha-GPC's potential benefits in supporting neuron health post-stroke, and it raises intriguing questions about how different treatments can work in a complementary or competitive manner.
Read More
3
We set out to explore how the use of L-α glycerylphosphorylcholine (α-GPC) affects stroke risk over a 10-year period. This retrospective cohort study looked at a large population from South Korea, including over 12 million men and women aged 50 and older, all of whom did not have a history of stroke or Alzheimer's disease.
Participants were categorized based on whether they were prescribed α-GPC between 2006 and 2008. From there, we matched those who used α-GPC with nonusers to create a balanced comparison. Notably, we found that those who took α-GPC had a higher risk of experiencing a stroke—this included both total strokes and specific types like ischemic and hemorrhagic strokes.
The results indicated a dose-response relationship, which means that the longer the duration of α-GPC use, the greater the risk of stroke observed. These findings raise important questions about the safety of α-GPC, especially considering its common use among older adults seeking cognitive benefits. Future research could help us understand the underlying mechanisms that contribute to this increased risk.
Participants were categorized based on whether they were prescribed α-GPC between 2006 and 2008. From there, we matched those who used α-GPC with nonusers to create a balanced comparison. Notably, we found that those who took α-GPC had a higher risk of experiencing a stroke—this included both total strokes and specific types like ischemic and hemorrhagic strokes.
The results indicated a dose-response relationship, which means that the longer the duration of α-GPC use, the greater the risk of stroke observed. These findings raise important questions about the safety of α-GPC, especially considering its common use among older adults seeking cognitive benefits. Future research could help us understand the underlying mechanisms that contribute to this increased risk.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 16 Reviews
7.7
- All Reviews
- Positive Reviews
- Negative Reviews
9
Restores recovery
21 people found this helpful
An excellent remedy for my seriously ill child, helping to restore memory, speech, and mood. We have seen consistent improvement over 1.5 years. It's particularly beneficial for those recovering from stroke or TBI, with no side effects like headaches.
Read More
9
Enhances cognitive function
12 people found this helpful
Alpha-GPC is essential for brain health, providing choline for cell membranes and increasing acetylcholine levels. After my mother's stroke, it significantly aided her recovery. Initially, she took 1200 mg daily for six months and now alternates it with other nootropics.
Read More
9
Improved condition
2 people found this helpful
I combined this with citicoline for my mother’s stroke recovery. It's excellent — her foggy memory is clearing, and she’s more active. I experienced significant effects too, feeling more energetic and calm without drowsiness.
Read More
9
Supports brain health
1 people found this helpful
This supplement is crucial for brain health, offering protection against stroke and Alzheimer's. It's easy to take with a reasonable dosage and great quality. I'm very satisfied.
Read More
9
Enhanced cognitive function
Alpha-GPC is essential for brain health. It nourishes the nervous system and supports stroke recovery. My mother took it daily after her stroke, and I believe it significantly aided her recovery.
Read More
Frequently Asked Questions
9
Restores recovery
21 people found this helpful
An excellent remedy for my seriously ill child, helping to restore memory, speech, and mood. We have seen consistent improvement over 1.5 years. It's particularly beneficial for those recovering from stroke or TBI, with no side effects like headaches.
9
Enhances cognitive function
12 people found this helpful
Alpha-GPC is essential for brain health, providing choline for cell membranes and increasing acetylcholine levels. After my mother's stroke, it significantly aided her recovery. Initially, she took 1200 mg daily for six months and now alternates it with other nootropics.
9
Improved condition
2 people found this helpful
I combined this with citicoline for my mother’s stroke recovery. It's excellent — her foggy memory is clearing, and she’s more active. I experienced significant effects too, feeling more energetic and calm without drowsiness.
7.5
Increases performance
9 people found this helpful
I purchased this supplement for an elderly individual who suffered a stroke; it noticeably increased their performance and vigour.
6
Improves memory
42 people found this helpful
Alpha GPC significantly enhances short-term memory! I take it daily with other supplements, and I find it helps with forgetfulness and memory issues. Stress and health problems can worsen memory, so I highly recommend this for various conditions, including stroke.
9
Enhanced cognitive function
Alpha-GPC is essential for brain health. It nourishes the nervous system and supports stroke recovery. My mother took it daily after her stroke, and I believe it significantly aided her recovery.
9
Supports brain health
1 people found this helpful
This supplement is crucial for brain health, offering protection against stroke and Alzheimer's. It's easy to take with a reasonable dosage and great quality. I'm very satisfied.
7.5
Best for recovery
8 people found this helpful
This is a highly digestible option for those with brain issues, best taken with fat during meals. It supports recovery from strokes and TBI effectively.
7.5
Memory improvement
Good quality; I bought it for my mother after her stroke. I hope it helps maintain her condition and possibly improve her memory and speech.
3
We set out to explore how the use of L-α glycerylphosphorylcholine (α-GPC) affects stroke risk over a 10-year period. This retrospective cohort study looked at a large population from South Korea, including over 12 million men and women aged 50 and older, all of whom did not have a history of stroke or Alzheimer's disease.
Participants were categorized based on whether they were prescribed α-GPC between 2006 and 2008. From there, we matched those who used α-GPC with nonusers to create a balanced comparison. Notably, we found that those who took α-GPC had a higher risk of experiencing a stroke—this included both total strokes and specific types like ischemic and hemorrhagic strokes.
The results indicated a dose-response relationship, which means that the longer the duration of α-GPC use, the greater the risk of stroke observed. These findings raise important questions about the safety of α-GPC, especially considering its common use among older adults seeking cognitive benefits. Future research could help us understand the underlying mechanisms that contribute to this increased risk.
Participants were categorized based on whether they were prescribed α-GPC between 2006 and 2008. From there, we matched those who used α-GPC with nonusers to create a balanced comparison. Notably, we found that those who took α-GPC had a higher risk of experiencing a stroke—this included both total strokes and specific types like ischemic and hemorrhagic strokes.
The results indicated a dose-response relationship, which means that the longer the duration of α-GPC use, the greater the risk of stroke observed. These findings raise important questions about the safety of α-GPC, especially considering its common use among older adults seeking cognitive benefits. Future research could help us understand the underlying mechanisms that contribute to this increased risk.
8
We explored the effects of alpha-GPC on the brain's response to stroke by comparing its impact alongside other neuroprotective treatments. In conducting experimental studies on 18 rats, we induced temporary strokes by restricting blood flow in the brain.
Using light and electron microscopy, we examined the brain structures like the cerebral cortex and cerebellum to assess cell damage and recovery processes. We observed that alpha-GPC, as well as another agent called cerebrolysin, notably improved the resilience of neurons against ischemic damage. They seemed to slow down the process of cell death and foster adaptive changes, such as enhancing cellular structures responsible for protein synthesis and storage.
In contrast, treatments like piracetam and vinpocetine didn’t show the same protective benefits. The evidence indicated inadequate energy for cell repair in response to ischemia, leading to concerning signs of neuron stress and cellular damage, including issues in myelin and synapse structure.
Overall, our findings suggest that alpha-GPC plays a positive role in supporting cellular health during stroke conditions, offering hope for neuroprotective therapies in stroke care.
Using light and electron microscopy, we examined the brain structures like the cerebral cortex and cerebellum to assess cell damage and recovery processes. We observed that alpha-GPC, as well as another agent called cerebrolysin, notably improved the resilience of neurons against ischemic damage. They seemed to slow down the process of cell death and foster adaptive changes, such as enhancing cellular structures responsible for protein synthesis and storage.
In contrast, treatments like piracetam and vinpocetine didn’t show the same protective benefits. The evidence indicated inadequate energy for cell repair in response to ischemia, leading to concerning signs of neuron stress and cellular damage, including issues in myelin and synapse structure.
Overall, our findings suggest that alpha-GPC plays a positive role in supporting cellular health during stroke conditions, offering hope for neuroprotective therapies in stroke care.
8
We set out to understand how alpha-GPC, a neuroprotective drug, can affect stroke recovery by observing its impact on brain structure during ischemic stroke. The study involved 18 rats, where we induced temporary cerebral circulation blockage to mimic stroke conditions. We then treated these rats with alpha-GPC, along with other neurotrophic and nootropic drugs, including cerebrolysin and piracetam.
Our findings revealed that treatment with alpha-GPC led to improved resilience in neurons exposed to ischemic damage. We discovered signs of cellular adaptation and repair, such as changes in the ribosome count and structural integrity of organelles. Importantly, alpha-GPC seemed to prolong the survival of neurons and delay cell death, which suggests a positive role in stroke recovery.
In comparison, rats treated with piracetam and vinpocetin showed concerning signs of energy deficits and functional stress in their neurons, indicating those treatments may not be as effective during the acute phase of stroke. Overall, the study highlights alpha-GPC's potential benefits in supporting neuron health post-stroke, and it raises intriguing questions about how different treatments can work in a complementary or competitive manner.
Our findings revealed that treatment with alpha-GPC led to improved resilience in neurons exposed to ischemic damage. We discovered signs of cellular adaptation and repair, such as changes in the ribosome count and structural integrity of organelles. Importantly, alpha-GPC seemed to prolong the survival of neurons and delay cell death, which suggests a positive role in stroke recovery.
In comparison, rats treated with piracetam and vinpocetin showed concerning signs of energy deficits and functional stress in their neurons, indicating those treatments may not be as effective during the acute phase of stroke. Overall, the study highlights alpha-GPC's potential benefits in supporting neuron health post-stroke, and it raises intriguing questions about how different treatments can work in a complementary or competitive manner.
9
We investigated how alpha-glycerophosphocholine (alpha-GPC) can aid in recovery for individuals who have recently suffered strokes or transient ischemic attacks. In this multicenter clinical trial involving 2044 patients, alpha-GPC was given after the event—first through injections for 28 days and then as a daily oral supplement for five months.
Throughout the treatment, we measured cognitive recovery using various scales, including the Mathew Scale, Mini Mental State Test, Crichton Rating Scale, and Global Deterioration Scale. Over the course of just 28 days, patients showed significant improvements in their mental recovery, with the Mathew Scale score increasing by an impressive 15.9 points. By the end of the five-month study, we noticed that many participants achieved near-normal cognitive scores, with 71% experiencing no cognitive decline.
While some patients did report mild adverse effects like heartburn and nausea, the overall tolerability was excellent, with only 2.14% needing to discontinue treatment due to side effects. We learned that alpha-GPC has a promising role in supporting cognitive recovery following strokes and transient ischemic attacks, highlighting its potential benefits in rehabilitation settings.
Throughout the treatment, we measured cognitive recovery using various scales, including the Mathew Scale, Mini Mental State Test, Crichton Rating Scale, and Global Deterioration Scale. Over the course of just 28 days, patients showed significant improvements in their mental recovery, with the Mathew Scale score increasing by an impressive 15.9 points. By the end of the five-month study, we noticed that many participants achieved near-normal cognitive scores, with 71% experiencing no cognitive decline.
While some patients did report mild adverse effects like heartburn and nausea, the overall tolerability was excellent, with only 2.14% needing to discontinue treatment due to side effects. We learned that alpha-GPC has a promising role in supporting cognitive recovery following strokes and transient ischemic attacks, highlighting its potential benefits in rehabilitation settings.
References
- Lee G, Choi S, Chang J, Choi D, Son JS, et al. Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Netw Open. 2021;4:e2136008. doi:10.1001/jamanetworkopen.2021.36008
- Onishchenko LS, Gaikova ON, Yanishevskii SN. Changes at the focus of experimental ischemic stroke treated with neuroprotective agents. Neurosci Behav Physiol. 2008;38:49.
- Onishchenko LS, Gaĭkova ON, Ianishevskiĭ SN. [Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs]. Morfologiia. 2006;130:40.
- Barbagallo Sangiorgi G, Barbagallo M, Giordano M, Meli M, Panzarasa R. alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci. 1994;717:253.
